



Emerging Topics in *Clostridioides difficile* Infection: A One Health Problem

Guest Editor:

Dr. Simon D. Baines

Department of Clinical,
Pharmaceutical & Biological
Science, University of
Hertfordshire, Hatfield AL10 9AB,
UK

Deadline for manuscript
submissions:

20 September 2024

Message from the Guest Editor

Dear Colleagues,

Clostridium difficile infection (CDI) remains a substantial worldwide burden on healthcare systems, despite significant research and investment over the past four decades. We extend a warm invitation for comprehensive studies focusing on *C. difficile* isolation, characterization, and epidemiology in humans, animals, and the environment.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: AMR transmission and assessment, environmental sampling, animal transmission/infection studies, antimicrobial prescribing studies and their effect on *C. difficile* infection, transmission and carriage in humans and animals, and assessment of *C. difficile* contamination of foodstuffs. We also welcome submissions involving fundamental science laboratory studies, in vivo animal and human studies, or modeling studies.

We look forward to receiving your contributions.

Dr. Simon D. Baines

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)